Pulsed-field gel electrophoresis patterns of clinical and environmental
A cluster of 3 facial
The injection of filler materials such as hyaluronic acid into the subcutaneous tissue of the face has become one of the most commonly performed cosmetic procedures. Unlike injections for medications or vaccinations, however, the filler material is intended to remain at the injection site for an extended period of time. In this respect, filler materials resemble implants, and these injections may deserve strict adherence to sterile technique.
Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and are known to exist in municipal and hospital water systems.
After 2 cases of
For the purposes of this investigation, we defined a confirmed case as a patient with a skin/soft-tissue infection and a positive skin-aspirate culture for
Confirmed case 1 was a 48-year-old, otherwise healthy woman who underwent multiple facial injections in October 2008 from a syringe of Juvederm Ultra Plus (Allergan, Inc, Irvine, California) that had previously been split into 2 portions, as was common at the facility where she was treated. She sought medical attention approximately 24 hours later at a local emergency department, complaining of redness at the injection site. She was treated symptomatically and did not have further medical follow-up until 3 weeks later, when she sought treatment for facial redness, swelling, and drainage. Rapidly growing
Confirmed case 2 was a 46-year-old, otherwise healthy woman who underwent facial injections with an unopened syringe of Juvederm Ultra Plus in November 2008. Eighteen days later, she reported the onset of facial redness and itching. An aspirate of the right cheek grew
Presumptive case 1 was a 54-year-old, otherwise healthy woman who underwent injections of Juvederm Ultra from an unopened syringe in November 2008. Two weeks after the injections, she developed redness, warmth, swelling, and changes in skin texture at the injection site. A facial aspirate was obtained; mycobacterial cultures were sterile and routine culture demonstrated only
To determine whether additional cases had occurred at the clinic where the first 2 cases were confirmed, we reviewed appointment logs for all visits coded for dermal filler or other facial injections. Using a standardized questionnaire, phone interviews were conducted with all patients who received a dermal injection at this facility between October 1 and December 31, 2008. Twenty-eight unique individuals, including the original 3 patients described above, received Juvederm Ultra or Juvederm Ultra Plus at the clinic in October and November 2008. We interviewed 13 (52%) of the 25 other patients but identified no additional cases. We also interviewed 8 (50%) of the 16 additional patients who received an injection of other products within 1 day of the injection date in the confirmed cases. Among these 8, 1 patient who received a Restylane (Medicis, Inc, Scottsdale, Arizona) injection was suspected of having an NTM infection but to our knowledge did not seek medical attention.
To address our concern that a commercially distributed dermal filler product might be contaminated with
To assess whether other clusters had been noted nationally, we posted notices on listservs likely to be seen by plastic surgeons, dermatologists, and infectious disease providers. We asked readers to report confirmed or presumptive cases of soft tissue infection with
Public health staff visited the clinic site to assess procedures, review lot numbers, and collect specimens for laboratory testing. Environmental specimens collected on December 30, 2008, included tap water from the faucet of the primary exam treatment room; water from the ice-machine intake, as well as swabs of the intake and interior of the ice machine; samples of anesthetic creams stored in bulk containers; samples of topical disinfectants, including isopropyl alcohol and an ammonium/phenolic compound; samples of household disinfectant for nonhuman surfaces; and open bottles of saline solution from the exam room.
Our chart review of the 2 confirmed cases found that those patients were injected with Juvederm Ultra Plus from different lot numbers. The procedure records, however, did not detail the use of specific antiseptics, anesthetics, or the sequence in which topical products were used at each visit. A typical injection procedure was described as beginning with the application of EMLA (App Pharmaceuticals, Schaumberg, Illinois) or a similar topical anesthetic for 20 to 40 minutes. Subsequently, 70% isopropyl alcohol from multiuse containers was applied to intended injection sites for disinfection. In response to the first case, the disinfectant was changed to a quaternary ammonium/ phenolic compound in the beginning of November, suggesting that the second confirmed case received a different topical disinfectant. Next, most patients opted to apply ice contained in exam gloves or Ziplock-type bags to the intended injection site for further anesthetic effect. Finally, up to 50 injections were administered per session using 27- or 30-gauge needles; needles were changed every 3 to 4 injections, when they became dull. Although most needles were supplied with the dermal filler product, the clinic also stocked needles. After the injections, ice was typically again applied to the skin, followed by topical hydrocortisone and vitamin K cream. Both the topical anesthetics and hydrocortisone were purchased in bulk and repackaged in smaller containers. In response to the first case, the hydrocortisone cream and vitamin K stocks were discarded. The practitioner wore nonsterile gloves during dermal filler procedures.
Environmental specimens obtained from the clinic were sent to the Oregon State Public Health Laboratory for mycobacterial culture. The water samples were filtered through a 0.2-μm filter and the residue was resuspended in a smaller volume. The resuspended sediment was then plated on Middlebrook 7H10 agar.
The specimens from the confirmed cases and the environmental isolates were forwarded from the original laboratory to the Centers for Disease Control and Prevention (CDC) for identification by high-performance liquid chromatography (HPLC), full-length 16S rRNA and rpoB gene sequencing, and comparison by pulsed-field gel electrophoresis. Mycolic acid analysis of the isolates with HPLC yielded profiles representative of the
Our site investigation and procedural review suggested a potential mechanism for the introduction of contamination: ice made from tap water on site was applied after disinfection of the skin but before injection of the filler. Although the ice was sealed in Ziplock bags, leakage may have occurred, contaminating the skin surface and allowing for intradermal inoculation during the procedure. Other opportunities for tap water exposure of the injection site include rinsing of nonsterile equipment used in the procedure or the practitioner’s contamination of his non-sterile gloves.
The multiuse containers used to store topical agents could also have served as a source for
Although the infections described in this report resolved with prolonged antibiotic therapy, their occurrence highlights the necessity for sterile injection practices with such products. The Juvederm Ultra Plus guidelines identify antisepsis as the step immediately prior to injection of the product, and application of ice is suggested for pain control after, not prior to, injection.
Only
This retrospective investigation is subject to several limitations. First, the environmental investigation was incomplete. Because of the long incubation period of NTM infections, we did not become aware of this cluster until many weeks after the clinic visits. By the time the investigation began, we could not test the bulk anesthetics, disinfectants, and other topical products in use at the time of the dermal filler injections since they had been discarded. In addition, the ice machine in use at the time of the injections had also been replaced. Second, the patient medical records lacked sufficient detail for a case control study; we were unable to explore procedure-related risk factors, such as anesthetic choice or injection details, or patient-related risk factors, such as concurrent immunological or dermatological conditions among dermal filler recipients. Finally, although we did identify
These 3 cases of
The authors received no financial support for the research, authorship, or publication of this article.
The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.
Pulsed-field gel electrophoresis patterns of clinical and environmental